Baxter International Inc. BAX

NYSE · Healthcare · Medical - Instruments & Supplies

$25.39

Close on Fri, 20 Nov 2026 · market value $13.1B

What the price is betting on

Below its record

At $25, the price assumes revenue shrinks about 6.6% a year for five years, from $11.6B to about $8.7B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−6.6%
Analysts, next two years2.4%
Last 3 years4.2%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.9% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than BAX? Check up to 5 of your stocks at once, free, no account.

0$5B$10B$15B$11.6B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$37

Base

$41

Bull

$45

Today $25

  • Bear $37. Cash flow grows 0% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $41. Cash flow grows 2% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $45. Cash flow grows 4% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$11.4B$11.7B, on the path
  3. FY2027$10.7B$12B, on the path
  4. FY2028$9.9B$12.2B, on the path
  5. FY2029$9.3BNo estimate yet
  6. FY2030$8.7BThe full bet

Each year's revenue at −6.6% growth from $11.6B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Instruments & Supplies · listed on NYSE

Revenue, FY2025
$11.2B
Growth, 3 years a year
4.2%
Cash margin
2.9%
Net debt
$8B
Shares, 3-year change
+1.8%
Dividend yield
2.6%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.